Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new eye test match the gold standard for glaucoma?

NCT ID NCT07765147

Diagnosis Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study compares two visual field tests used to monitor glaucoma: the current standard Humphrey Visual Field Analyzer and the newer iCare COMPASS. About 28 people with glaucoma or related eye conditions will take both tests in the same visit, with the order alternating between participants. Researchers will compare key measurements, like mean deviation and pattern deviation, to see if the iCare COMPASS provides similar accuracy and any practical advantages.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Visual field testing with the iCare COMPASS device compared to the standard Humphrey Visual Field Analyzer
What this could lead to
If the iCare COMPASS proves as accurate as the current standard, it could offer a faster or more convenient way to monitor glaucoma and other eye conditions.
What could go wrong
This is a small, early-stage comparison study, so results may not apply broadly. The new device might not match the standard's accuracy or could have practical drawbacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Feb 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All consenting patients who arrive for glaucoma management appointments for objective(s) 2.1.1, 2.2.2 * Patient groups arriving for glaucoma management that will be targeted for enrollment include: glaucoma suspect patients, those with cataracts, optic atrophy, macular degeneration, macular pathology, and vascular diseases of the retina Exclusion Criteria: * Those who are unwilling or unable to provide consent * Those for which English is not their first language

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma 1, open angle, D (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma glaucoma 1, open angle, l open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma 1, open angle, D (disorder)

Contacts and locations

Locations

  • Eugene and Marilyn Glick Eye Institute

    Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.